An Open-Label, Phase 1 Study Evaluating the Safety and Pharmacokinetics of Pralatrexate in Relapsed/Refractory Advanced Solid Tumors or Advanced Lymphoma/Myeloma Patients with Mild, Moderate, and Severe Renal Impairment

被引：0
|
作者：
Kelly, Kevin R. [1 ]
Gabrail, Nashat Y. [2 ]
Edenfield, William J. [3 ]
Lockhart, A. Craig [4 ]
Olszanski, Anthony J. [5 ]
Reddy, Guru [6 ]
机构：
[1] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA
[2] Gabrail Canc Ctr, Canton, OH USA
[3] Canc Ctr Carolinas, Greenville, SC USA
[4] Washington Univ, Sch Med, St Louis, MO 63130 USA
[5] Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Lebanon, NH 03766 USA
[6] Spectrum Pharmaceut, Irvine, CA USA
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory solid tumors
    Galsky, M. D.
    Camacho, L. H.
    Chiorean, E. G.
    Mulkerin, D.
    Hong, D. S.
    Oh, W. K.
    Bajorin, D. F.
    ANNALS OF ONCOLOGY, 2012, 23 (04) : 1037 - U11
  • [42] A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function
    Slingerland, Marije
    Hess, Dagmar
    Clive, Sally
    Sharma, Sunil
    Sandstrom, Per
    Loman, Niklas
    Porro, Maria G.
    Mu, Song
    Waldron, Edward
    Valera, Sue-zette
    Gelderblom, Hans
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (05) : 1089 - 1098
  • [43] A phase I/II, open-label, multicenter study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of HB0036 in patients with advanced solid tumors
    Sun, Yuping
    Yu, Jinming
    Tolcher, Anthony W.
    Albany, Costantine
    Chaudhry, Arvind
    Dang, Qi
    Ye, Leiguang
    Yang, Fang
    Liu, Baogang
    Sun, Longhua
    Tang, Jianjun
    Xu, Lei
    Zhu, Xiangyang
    Yang, Yongmin
    Yang, Yang
    Zhan, Yifan
    Li, Benke
    Hou, Kexin
    Zheng, Yang, Sr.
    Wang, Jingjing
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [44] A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function
    Marije Slingerland
    Dagmar Hess
    Sally Clive
    Sunil Sharma
    Per Sandstrom
    Niklas Loman
    Maria G. Porro
    Song Mu
    Edward Waldron
    Sue-zette Valera
    Hans Gelderblom
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 1089 - 1098
  • [45] Safety, tolerability, pharmacokinetics, and antitumour activity of oleclumab in Japanese patients with advanced solid malignancies: a phase I, open-label study
    Kondo, Shunsuke
    Iwasa, Satoru
    Koyama, Takafumi
    Fujita, Tomoko
    Sugibayashi, Ko
    Murayama, Kosho
    Yamamoto, Noboru
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (12) : 1795 - 1804
  • [46] Safety and pharmacokinetics of imaradenant (AZD4635) in Japanese patients with advanced solid malignancies: a phase I, open-label study
    Nobuaki Matsubara
    Shota Kusuhara
    Noboru Yamamoto
    Kazuki Sudo
    Masahiko Yanagita
    Kosho Murayama
    Hisashi Kawasumi
    Deanna L. Russell
    Da Yin
    Toshio Shimizu
    Cancer Chemotherapy and Pharmacology, 2024, 93 : 341 - 352
  • [47] A Phase 1, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics of Iberdomide in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared with Healthy Subjects
    Cheng, Yiming
    Ye, Ying
    Gaudy, Allison
    Ghosh, Atalanta
    Xue, Yongjun
    Wang, Alice
    Zhou, Simon
    Li, Yan
    CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2023, 15 : 9 - 19
  • [48] Safety, tolerability, pharmacokinetics, and antitumour activity of oleclumab in Japanese patients with advanced solid malignancies: a phase I, open-label study
    Shunsuke Kondo
    Satoru Iwasa
    Takafumi Koyama
    Tomoko Fujita
    Ko Sugibayashi
    Kosho Murayama
    Noboru Yamamoto
    International Journal of Clinical Oncology, 2022, 27 : 1795 - 1804
  • [49] Safety and pharmacokinetics of imaradenant (AZD4635) in Japanese patients with advanced solid malignancies: a phase I, open-label study
    Matsubara, Nobuaki
    Kusuhara, Shota
    Yamamoto, Noboru
    Sudo, Kazuki
    Yanagita, Masahiko
    Murayama, Kosho
    Kawasumi, Hisashi
    Russell, Deanna L.
    Yin, Da
    Shimizu, Toshio
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 93 (04) : 341 - 352
  • [50] A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors
    Azzoli, Christopher G.
    Krug, Lee M.
    Gomez, Jorge
    Miller, Vincent A.
    Kris, Mark G.
    Ginsberg, Michelle S.
    Henry, Roxanne
    Jones, Jessica
    Tyson, Leslie
    Dunne, Megan
    Pizzo, Barbara
    Farmer, Amy
    Venkatraman, Ennapadam
    Steffen, Robert
    Sirotnak, F. M.
    CLINICAL CANCER RESEARCH, 2007, 13 (09) : 2692 - 2698
12345